Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 1;21(1):694.
doi: 10.1186/s13063-020-04613-7.

Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process

Affiliations

Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process

Miles D Witham et al. Trials. .

Abstract

Background: Participants in clinical research studies often do not reflect the populations for which healthcare interventions are needed or will be used. Enhancing representation of under-served groups in clinical research is important to ensure that research findings are widely applicable. We describe a multicomponent workstream project to improve representation of under-served groups in clinical trials.

Methods: The project comprised three main strands: (1) a targeted scoping review of literature to identify previous work characterising under-served groups and barriers to inclusion, (2) surveys of professional stakeholders and participant representative groups involved in research delivery to refine these initial findings and identify examples of innovation and good practice and (3) a series of workshops bringing together key stakeholders from funding, design, delivery and participant groups to reach consensus on definitions, barriers and a strategic roadmap for future work. The work was commissioned by the UK National Institute for Health Research Clinical Research Network. Output from these strands was integrated by a steering committee to generate a series of goals, workstream plans and a strategic roadmap for future development work in this area.

Results: 'Under-served groups' was identified and agreed by the stakeholder group as the preferred term. Three-quarters of stakeholders felt that a clear definition of under-served groups did not currently exist; definition was challenging and context-specific, but exemplar groups (e.g. those with language barriers or mental illness) were identified as under-served. Barriers to successful inclusion of under-served groups could be clustered into communication between research teams and participant groups; how trials are designed and delivered, differing agendas of research teams and participant groups; and lack of trust in the research process. Four key goals for future work were identified: building long-term relationships with under-served groups, developing training resources to improve design and delivery of trials for under-served groups, developing infrastructure and systems to support this work and working with funders, regulators and other stakeholders to remove barriers to inclusion.

Conclusions: The work of the INCLUDE group over the next 12 months will build on these findings by generating resources customised for different under-served groups to improve the representativeness of trial populations.

Keywords: Recruitment; Roadmap; Stakeholder; Trials; Under-served.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Components of the programme. SG steering group
Fig. 2
Fig. 2
Workstreams to take forward in the programme
Fig. 3
Fig. 3
Roadmap to guide initiatives to improve inclusion of underserved groups into clinical research. Processes are embedded in the context of ethics and regulatory requirements and evolving digital technology developments. Boxes represent key points for considering inclusion of underserved groups over the lifecourse of the study

References

    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406. doi: 10.1016/j.jclinepi.2010.07.015. - DOI - PubMed
    1. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171:550–556. doi: 10.1001/archinternmed.2011.31. - DOI - PubMed
    1. Treweek S, Dryden R, McCowan C, Harrow A, Thompson A. Do participants in major breast cancer trials reflect the breast cancer patient population? Eur J Cancer. 2015;51:90714. doi: 10.1016/j.ejca.2015.01.064. - DOI - PubMed
    1. Khunti K, Bellary S, Karamat MA, Patel K, Patel V, Jones A, et al. Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in type 2 diabetes. Diabet Med. 2017;34:64–68. doi: 10.1111/dme.13103. - DOI - PubMed
    1. Ferdinand KC, Elkayam U, Mancini D, Ofili E, Piña I, Anand I. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. Am J Cardiol. 2014;114:151–159. doi: 10.1016/j.amjcard.2014.04.018. - DOI - PubMed